Galera Therapeutics Inc., of Malvern, Pa., said it received an additional $5 million in funding from Enso Ventures bringing its series B financing to $42 million. The company generated $37 million from its original series B round in October 2015. The investment capital will be used to advance the company's lead candidate GC4419 in a phase IIb trial that is currently enrolling head and neck cancer patients receiving chemoradiation therapy to prevent against oral mucositis. The proceeds will also support continued development of Galera's pipeline of selective dismutase mimetics to modulate oxygen metabolic pathways. (See BioWorld Today, Oct. 15, 2015.)